Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS87T9)

Drug Name
FK-838 Drug Info
Synonyms
FK-838; FK 838; 131185-37-0; CHEMBL292917; 6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazinebutyric acid; 6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazineboutanoic acid; C21H18N4O3; 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-; 1(6H)-Pyridazinebutanoicacid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-; FKJPZJACCBMNKZ-UHFFFAOYSA-N; AC1MHZMV; ACMC-20mtz5; SCHEMBL2641189; CTK0H8748; DTXSID60156936; BDBM50079654; AKOS030617923; LS-172794; L004106
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
3035594
CAS Number
CAS 131185-37-0
TTD Drug ID
DMS87T9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adenosine A1 receptor (ADORA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [3]
Rolofylline DMSZPR3 Heart failure BD10-BD13 Phase 3 [4]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [5]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [6]
SELODENOSON DMQM3IX Cardiac arrhythmias BC9Z Phase 2 [7]
Apaxifylline DMQMV9F Cognitive impairment 6D71 Phase 2 [8]
SLV320 DM867BJ Heart failure BD10-BD13 Phase 2 [9]
DTI-0009 DMV84OK Atrial fibrillation BC81.3 Phase 2 [7]
Capadenoson DMYWO62 Atrial fibrillation BC81.3 Phase 2 [10]
BAY 1067197 DM4JGNH Heart failure BD10-BD13 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A1 receptor (ADORA1) TTK25J1 AA1R_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005145)
2 An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistan... Br J Pharmacol. 2003 Aug;139(8):1383-8.
3 Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
4 Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
5 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
6 Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
7 Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
9 Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
10 A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
11 Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.